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ABSTRAcT
The aim of the present study was to develop and validate a 
High-Performance liquid Chromatography (HPlC) method 
for the determination of voriconazole in drug substances and 
in situ gel. a mixture of acetonitrile and ultrapure water (50:50) 
(v/v) was used as mobile phase. The column was a C18 column 
(150x4.6mm with 5µm particles). The eluent was monitored 
with uV detection at 256 nm and flow rate was set to 1 ml/
min. The method was validated partially with respect to system 
suitability, linearity, limits of detection (lOd) and quantitation 
(lOQ), precision, accuracy, specificity, selectivity and stability. 
Obtained results showed that the analytical method had good 
linearity, accuracy, precision, selectivity and stability. analytical 
method development results indicated that the lOd was 0.022 
µg/ml; lOQ was 0.065 µg/ml and assay exhibited a linear range 
of 1- 30 µg/ml.
Keywords: Voriconazole, HPlC, method, validation
INTRODUcTION
Voriconazole is chemically named as [(2r,3s)-2-(2,4-
difluorophenyl)-3-(5-fluoro-4-pyrimidinyl)-1-(1H-1,2,4-
triazol-1-yl)-2-butanol] with an empirical formula of 
C16H14F3N5O (Figure 1) (1) and its  molecular weight is 349.3 
da (2). ıt is the Biopharmaceutics Classification system (BCs) 
class ıı antifungal drug with low aqueous solubility (3).
Figure 1. Chemical structure of voriconazole molecule 
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antifungal drugs carrying azole rings are the most 
commonly used agents in terms of treating superficial and 
systemic fungal infections. They work through a common 
mechanism of action; they selectively inhibit the synthesis 
of a major component of fungal cell; ergosterol and they 
alter the permeability of cell membrane by binding to the 
phospholipids of fungal cell membrane (4, 5). Voriconazole, 
a new-generation antifungal agent, possesses phenomenal 
characteristics like broad-spectrum activity against resistant 
fungal species, and acceptable tolerability. almost 100% 
in vitro susceptibility was observed against various fungal 
isolates associated with keratitis and endophthalmitis. 
Moreover, studies suggested an excellent efficacy of 
voriconazole against several ocular mycoses following topical 
administration (6).
Fungal keratitis is a leading cause of serious ocular 
morbidity and blindness. ıt shows worldwide spread, but 
is more common in the tropics and subtropical regions. ın 
fungal keratitis, early diagnosis and antifungal therapy is 
necessary in terms of preventing further complications such 
as hypopyon formation, endophthalmitis, or loss of vision 
(7). Whilst reports on the use of 1% voriconazole eye drops 
in the management of ophthalmic fungal keratitis have been 
promising, the voriconazole concentrations achieved in the 
eye were not sufficiently high to treat all types of fungal 
keratitis (8). 
Voriconazole was studied for HPlC method and 
validation for bulk samples and tablet dosage forms (9, 10). 
Furthermore voriconazole was determined in human plasma 
and serum by HPlC for application to pharmacokinetic 
studies of voriconazole (11, 12, 13). although several HPlC 
methods can be found in the literature for Voriconazole, 
to date, no HPlC methods for voriconazole determination 
in in situ gel formulation have been described. ın the 
present investigation, a simple, optimized, and validated 
HPlC method was developed for the standardization of 
voriconazole. The aim of this study was to develop and 
validate an analytical method for voriconazole in bulk and 
in situ gel (containing poloxamer 188, poloxamer 407 and 
benzalkonium chloride), which is a novel drug delivery 
system for voriconazole active ingredient.  
EXpERIMENTAl
Materials
HPlC grade acetonitrile (sigma, germany) was used 
for HPlC. Voriconazole was purchased from sigma, 
usa. Poloxamer 407 and poloxamer 188 were purchased 
from BasF, turkey. all the other chemicals and solvents 
were analytical or HPlC reagent grade. ultrapure water 
was obtained from direct-Q® Water Purification system, 
germany.
Instrumentation
The HPlC system consisted of a gradient pump, thermostable 
column department and a uV detector supplied by agilent 
1100. The column was a C18 column (150x4.6mm,5µm) (gl 
sciences, Japan). The column compartment was temperature 
controlled and uV detector was employed throughout 
the analysis. Chromatographic data was acquired by using 
empower software. 
chromatographic conditions
The voriconazole samples were analyzed using a uV 
spectrometer (uV-1800, shimadzu, Japan) covering the range 
of 190–400 nm. The optimum wavelength selected was 256 
nm (Figure 2), which represents the wavelength of maximum 
response for all impurities in order to permit simultaneous 
determination of related impurities of voriconazole. 
Figure 2. uV spectrum of voriconazole
The mobile phase was prepared by mixing acetonitrile 
and ultrapure water (50:50) (v/v) with flow rate of 1 ml/min 
(14). all solutions were filtered through a 0.45 μm membrane 
(sartorius, germany) prior to use. The flow rate was 1 ml/
min and the column temperature was maintained at 25±1 
°C. The volume of injection was adjusted 10 μl. The column 
was equilibrated for at least 40 min with the mobile phase 
flowing through the system before the injection of the drug 
standards. The run time was set at 10 min with the system 
operating at air-conditioned temperature (25±1 °C).
Üstündağ Okur et al.
HPLC method for voriconazoleMarmara Pharm J 20: 79-85, 2016 81
preparation of stock solutions and standard working 
solution
stock solutions of voriconazole (100 μg/ml) was prepared by 
dissolving 6.2 mg of drug in 62 ml mixture of acetonitrile and 
ultrapure water (50:50) (v/v). The standard solutions were 
stored at 4±1 °C in a clear glass volumetric flask and light-
protected with aluminum foil. Voriconazole concentrations 
in the working solution chosen for the calibration curves were 
1, 3, 5, 8, 11, 14, 17, 20, 25 and 30 μg/ml. Quality control (QC) 
samples (of low, medium and high concentration) at 8, 11 and 
14 μg/ml were prepared in the same ways as the calibration 
standards. These working solutions were prepared fresh daily 
by making further dilutions of the stock solution in mobile 
phase. all samples were filtered through an aqueous 0.2 µm 
pore size membrane filter before injection.
Hplc Method Validation
The described method was validated partially with respect 
to system suitability, linearity, limit of detection (lOd) and 
quantitation (lOQ), precision, accuracy and specificity, 
selectivity and stability.
Specificity/Selectivity
The specificity of an analytical method is its ability to measure 
accurately and specifically the analyte in the presence of 
components that may be expected to be present in the sample 
matrix. to evaluate the specificity of the analytical method, the 
blank and drug loaded pharmaceutical formulation has been 
injected into the chromatographic system. These parameters were 
determined by comparing the chromatograms of the voriconazole 
standard, drug loaded in situ gel and blank in situ gel (15).
linearity
The linearity between peak area and concentration was 
analyzed using calibration curve obtained from standard 
solutions of voriconazole (1 to 30 μg/ml) (16). ın addition 
the linearity was evaluated by linear regression analysis, 
which was calculated by the least-square regression analysis.
Accuracy
The accuracy of an analytical method is the closeness of 
test results obtained by the method to the true value and is 
defined recovery. The prepared three standard solutions (8, 
11, 14 μg/ml) were injected five times at different levels as a 
test sample (17).
precision
8 μg/ml voriconazole solution and voriconazole loaded in 
situ gel was injected ten times in order to evaluate method 
precision, standard deviation (sd) and coefficient of 
variation (CV%) (16). For intermediate precision study, 
three samples which different concentration were prepared 
and injected ten times. ıntermediate precision is a measure 
of repeatability within laboratory variation. ın order to 
evaluate the intermediate precision parameter, six different 
test solutions prepared by different analysts using the same 
drug substance sample have been analyzed by using different 
chromatographs and the difference of the experimental 
results obtained by two analysts has been calculated (18).
Stability of the Solution
a sample solution of voriconazole was prepared and analyzed 
initially and also at the end of the 48 hour by keeping the 
solution at room temperature (19).
Robustness
to determine the robustness of the developed method, 
experimental conditions were deliberately altered (18). The 
flow rate of the mobile phase was 1.0 ml/min. to study 
the effect of flow rate on the resolution, flow was ranged in 
between 0.5 to 1.5 ml/min. 
RESUlTS AND DIScUSSION
The uV spectrum of voriconazole in mobile phase was 
scanned in the region between 190 to 400 nm. The λmax 
was determined at 256 nm (Figure 2). ın this method the 
retention time of voriconazole was about 4.09 min. 
The specificity and selectivity describe the capacity for 
each concentration of the analytical method to measure the 
drug in the presence of impurities, excipients, degradation 
products or matrix components. These parameters were 
determined by comparing the chromatograms of the 
voriconazole standard, drug loaded in situ gel and blank in 
situ gel.  
There was no interference from the blank and also from the 
impurities at voriconazole peaks. The chromatogram of the 
voriconazole standard presented a peak in the retention time 
of 4.09 (Figure 3a). The chromatogram of standard solution 
without voriconazole is Figure 3B .The chromatogram of 
voriconazole loaded in situ gel sample (Figure 3C) showed 
a peak and retention time similar to voriconazole standard. 
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The chromatogram of in situ gel without voriconazole is 
Figure 3d.
Figure 3. The chromatograms obtained in the presence (a), 
and absence (B) of voriconazole in standard solution, standard 
solution of voriconazole loaded in situ gel (C) and blank in 
situ gel (d). (Concentration of voriconazole (8 μg/ml))
ten points calibration graphs was constructed covering 
a concentration range 1-30 μg/ml for standard solution 
of bulk voriconazole. Three independent determinations 
were performed at each concentration. data indicate that 
the voriconazole peak areas are linear over concentration 
range of 1- 30 μg/ml. linear relationship between the peak 
area and concentration of voriconazole was observed. The 
standard deviation of the slope and intercept were low. The 
determination coefficient r2 for regression line is 0.999 with 
slope of 13.764x and y + intercept of - 0.656 for standard 
solution of voricanozole. The analyses of calibration are 
shown in Figure 4.
 
Figure 4. The regression line for voriconazole 
Precision studies for an analytical procedure are being 
done in terms of expressing the closeness of agreement 
between series of measurements, which are obtained from 
same homogenous samples under the same conditions. 
ın terms of method precision study of our experiment, 
8 μg/ml solutions were injected ten times into the system 
and the percentage of recovery was evaluated. as table 1 
shows, the percentage of mean recovery value was 99.09 with 
standard deviation of 0.29 for bulk voriconazole solution. 
Furthermore, the percentage of mean recovery value was 
97.41 with standard deviation of 0.22 for voriconazole 
loaded in situ gel. since the percentage of recovery has 
been found almost 100 and the standard deviation less than 
the acceptance criteria which is 2%, the analysis system 
for the determination of assay is verified. low values of 
standard deviation denoted very good repeatability of the 
measurement. Thus it was showing that the equipment used 
for the study was correct and hence the developed analytical 
method is highly repetitive.
a
C
B
d
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Table 1. The results of precision study for 8 μg/mL bulk 
voriconazole solution and voriconazole loaded in situ gel
Recovery (%)
injection times of
test solution
bulk voriconazole 
solution
voriconazole 
loaded in situ 
gel
1 98.89 97.13
2 98.72 97.32
3 98.82 97.32
4 99.33 97.5
5 99.26 97.41
6 99.38 97.95
7 99.52 97.41
8 98.82 97.23
9 98.97 97.41
10 99.15 97.41
Mean 99.09 97.41
SD 0.29 0.22
RSD % 0.29 0.22
ıntermediate precision study can be defined as 
measurement of repeatability within laboratory variations. 
ın order to evaluate the intermediate precision parameter, 
two analysts prepared six different samples with the same 
concentration (table 2).
Table 2. ıntermediate precision study results (8 μg/mL)
Test 
Solution
Voriconazole[%]
Analyst 1
Voriconazole[%]
Analyst 2
1 109.72 105.45
2 107.82 106.90
3 107.89 107.96
4 111.2 109.49
5 108.47 108.99
6 107.16 108.37
Mean 108.84 107.95
SD 1.77 1.37
RSD % 1.63 1.27
The accuracy of an analytical method is the closeness 
of test results obtained by that method to the true value. 
The accuracy of an analytical method can be defined as the 
ratio of obtained concentration values to true values and its 
percentage of recovery (20). 
The mean recovery data of voriconazole in sample were 
within the range of 99.49 and 100.7 %. The mean % r.s.d. 
was in between 0.09 to 0.24  % satisfying the acceptance 
criteria for the study. Hence the accuracy of the method was 
confirmed, this developed method can be used for further 
studies. recovery (%) of voriconazole was given in table 3.
Table 3. Percent recovery and coefficient of variations
Recovery (%)
Voriconazole
concentrations
Injection 
times of 
test
solution
Bulk 
Voriconazole 
loaded in situ 
gel
8 μg/ml
1 99.66 97.13
2 99.65 97.32
3 99.64 97.32
4 99.13 97.5
5 99.38 97.41
Mean 99.49 97.33
SD 0.24 0.13
RSD % 0.24 0.14
11 μg/ml
1 100.63 98.32
2 100.43 98.38
3 100.44 98.19
4 100.42 97.92
5 100.51 98.19
Mean 100.49 98.2
SD 0.09 0.18
RSD % 0.09 0.18
14 μg/ml
1 100.83 98.27
2 100.59 97.75
3 100.48 97.64
4 100.65 97.38
5 100.94 97.38
Mean 100.7 97.69
SD 0.18 0.36
RSD % 0.18 0.37
samples should be tested over at least a 48 hour period 
(depends on intended use), and quantitation of components 
should be determined by comparison to freshly prepared 
standards. The stability of voriconazole in 11 μg/ml standard 
solutions was determined by storing the solutions at ambient 
temperature (25 ± 1 0C). after two successive days of 
storage, the freshly prepared solution and the previous ones 
were injected into the system and afterwards the data were 
compared to each other. ın each case, it could be noticed 
that solutions were stable for 48 hours. Furthermore, the 
percentage of mean recovery of freshly prepared and 48 
hour old of 11 μg/ml solution was found 100.05 and 100.10, 
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respectively. This denotes that voriconazole in stable in 
standard solutions for at least 2 days at ambient temperature. 
For 11μg/ml standard solutions of voriconazole loaded in 
situ gel, results of percentage recovery for freshly prepared 
and 48 hour old solutions are shown in table 4.
Table 4. The percentage of mean recovery of two 11 μg/ml 
solutions, which are prepared in two different days
Injection 
times
Bulk Voriconazole 
solution
Voriconazole loaded
in situ gel
Recovery 
(%) 0 h
Recovery 
(%) 
48 h
Recovery 
(%)  
0 h
Recovery (%) 
48 h
1 99.91 99.79 97.13 100.86
2 100.05 99.87 97.32 100.86
3 100.00 100.18 97.32 100.77
4 100.3 100.14 97.5 100.95
5 100.02 100.13 97.41 100.68
6 100.11 100.4 97.95 100.77
7 100.02 100.32 97.41 101.22
8 99.89 99.92 97.23 100.95
9 100.08 99.98 97.41 100.86
10 100.15 100.27 97.41 101.13
Mean 100.05 100.10 97.41 100.9
SD 0.12 0.20 0.22 0.17
RSD % 0.12 0.20 0.22 0.17
 
The limit of detection (lOd) and limit of Quantitation 
(lOQ) tests for the procedure are performed on samples 
containing very low concentrations of analyses. lOd is 
defined as the lowest amount of analyze that can be detected 
above baseline noise; typically, three times the noise level. 
lOQ is defined as the lowest amount of analyze which can be 
reproducibly quantitated above the baseline noise, that gives 
s/N = 10 (21). lOd was found 0.022 µg/ml and lOQ was 
found 0.065 µg/ml.
to evaluate the effect of the flow rate on assay results, 
11 μg/ml voriconazole solution was analyzed at different 
flow rates. Changes on the flow rate showed understandable 
and proportional extension over the retention time of peaks 
(table 5).
Table 5. Effect of the flow rate variation on assay results
Flow rate Retention time
0.5 ml/min 8.43
0.8 ml/min 5.15
1 ml/min 4.1
1.2 ml/min 3.43
1.5 ml/min 2.75
cONclUSION
a simple, precise, accurate, reproducible, highly sensitive and 
effective stability indicating HPlC method was developed 
and validated for simultaneous quantitative determination 
of voriconazole. The method was validated for accuracy, 
precision, specificity, and linearity. The developed method 
is stability indicating and it is lOd and lOQ values are in 
the range of 0.022 μg/ml and 0.065 μg/ml for voriconazole, 
respectively. ın this study, the high recovery and low relative 
standard deviation confirm the suitability of the method for 
determination of voriconazole in pharmaceutical dosage 
forms. ın conclusion, this method can be used for the routine 
determination of voriconazole in pure and pharmaceutical 
formulations.
Acknowledgements
The authors would like to acknowledge ıstanbul Medipol 
university rEMEr for enabling us to use its laboratory 
instruments.
Declaration of Interest 
The authors declare no conflict of interest.
Vorikonazol Etken Maddesi Ve Farmasötik Formülasyonları 
İçin Hplc Yönteminin Geliştirilmesi Ve Validasyonu 
ÖZ
Mevcut çalışmanın amacı, vorikonazol etkin maddesi 
ve farmasötik formları için yüksek performanslı sıvı 
kromatografisi kullanılarak bir analitik yöntemin geliştirilmesi 
ve validasyonunu kapsamaktadır. Mobil faz olarak asetonitril ve 
ultra saf su karışımı (50:50) kullanılmıştır. analiz işlemlerinde 
C18 kolonu (150x4.6mm; 5µm) kullanılmıştır. Eluent, dakikada 
1ml’ ye ayarlanan akış hızı ve 256 nm dalga boyunda uV 
detektör yardımıyla gözlenmiştir. Yöntemin  validasyon 
işlemleri için sırasıyla sisteme uygunluk, doğrusallık, tespit ve 
miktar limiti, kesinlik, özgünlük, doğruluk, seçicilik ve stabilite 
deneyleri yapılmıştır.  Elde edilen sonuçlar, geliştirilen analitik 
yöntemin iyi düzeyde doğrusallığa, doğruluğa, kesinliğe, 
seçiciliğe ve stabiliteye sahip olduğunu göstermiştir. analitik 
yöntem geliştirme sonuçları, 1-30µg/ml doğrusal aralıkta, 
tespit sınırını 0.02176 µg/ml ve miktar sınırını ise 0.06528 µg/
ml olarak göstermiştir.
 Anahtar kelimeler: vorikonazol, HPlC yöntem validasyonu
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